Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,534 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Di Noia V, D'Argento E, Pilotto S, Vita E, Ferrara MG, Damiano P, Ribelli M, Cannella A, Virtuoso A, Fattorossi A, Ceresoli GL, Milella M, Beretta GD, Tortora G, Bria E. Di Noia V, et al. Among authors: vita e. Cancer Immunol Immunother. 2021 Jun;70(6):1583-1592. doi: 10.1007/s00262-020-02788-1. Epub 2020 Nov 24. Cancer Immunol Immunother. 2021. PMID: 33231726 Free PMC article. Clinical Trial.
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis.
Rossi A, Noia VD, Gkountakos A, D'Argento E, Sartori G, Vita E, Monteverdi S, Lombardo F, Iacovelli R, Carbognin L, Sperduti I, Milella M, Tortora G, Bria E, Pilotto S. Rossi A, et al. Among authors: vita e. Immunotherapy. 2019 Jul;11(10):921-930. doi: 10.2217/imt-2018-0198. Epub 2019 Jun 3. Immunotherapy. 2019. PMID: 31155995
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Zanelli F, Guaitoli G, Garassino MC, Ciccone LP, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzutilo EG, Bartoli G, Baldessari C, Novello S, Bria E, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M. Facchinetti F, et al. Among authors: vita e. Eur J Cancer. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023. Epub 2020 Mar 25. Eur J Cancer. 2020. PMID: 32220780
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, Russo GL, Signorelli D, Toschi L, Milella M, Pilotto S, Bria E, Proto C, Marinello A, Randon G, Rossi S, Vita E, Sartori G, D'Argento E, Qako E, Giaiacopi E, Ghilardi L, Bettini AC, Rapacchi E, Mazzoni F, Lavacchi D, Scotti V, Ciccone LP, De Tursi M, Di Marino P, Santini D, Russano M, Bordi P, Di Maio M, Audisio M, Filetti M, Giusti R, Berardi R, Fiordoliva I, Cerea G, Pizzutilo EG, Bearz A, De Carlo E, Cecere F, Renna D, Camisa R, Caruso G, Ficorella C, Banna GL, Cortinovis D, Brighenti M, Garassino MC, Tiseo M. Bersanelli M, et al. Among authors: vita e. Lung Cancer. 2020 Dec;150:123-131. doi: 10.1016/j.lungcan.2020.10.008. Epub 2020 Oct 22. Lung Cancer. 2020. PMID: 33130353 Free article.
Prognostic Factors and Long-Term Survival in Locally Advanced NSCLC with Pathological Complete Response after Surgical Resection Following Neoadjuvant Therapy.
Lococo F, Sassorossi C, Nachira D, Chiappetta M, Petracca Ciavarella L, Vita E, Boldrini L, Evangelista J, Cesario A, Bria E, Margaritora S. Lococo F, et al. Among authors: vita e. Cancers (Basel). 2020 Nov 30;12(12):3572. doi: 10.3390/cancers12123572. Cancers (Basel). 2020. PMID: 33265905 Free PMC article.
13,534 results
You have reached the last available page of results. Please see the User Guide for more information.